Summary. We report a patient who was treated with recombinant (r)-hirudin for heparin-induced thrombocytopenia and developed a¯ush reaction twice upon re-exposure to 25 mg of subcutaneous r-hirudin. Antihirudin IgG antibodies developed. The patient received 50 mg of PEG-hirudin subcutaneously over 2 days. No side-effects occurred. The level of IgG antihirudin antibodies increased. Ecarin clotting time and thrombin inhibition S2238 assay were not in¯uenced by the patient's IgG antihirudin antibody. PEG-hirudin may be used in patients with intolerance to r-hirudin because of a dissociation of the allergenic and immunogenic properties of the pegylated drug.
Hirudin is extracted from the salivary glands of the leech Hirudo medicinalis and inhibits blood coagulation by binding to and inactivating thrombin (Markwardt, 1994) . Today, it is produced by recombinant technology. Recently, an acute urticaria reaction caused by subcutaneous recombinant (r)-hirudin (Bircher et al, 1996) and contact allergy to hirudin contained in topical medications have been reported (Dejobert et al, 1991) .
Heparin-induced thrombocytopenia (HIT) and thrombosis is treated with danaparoid or r-hirudin (Harenberg et al, 1997; Greinacher et al, 1999) . Pegylated (PEG) hirudin was developed to increase the half-life of r-hirudin (Esslinger et al, 1997) . The pegylation of drugs also results in reduced allergenicity. Here, we report the use of PEG-hirudin in a patient with¯ush reaction to subcutaneous r-hirudin.
CASE REPORT
A 62-year-old male patient, with a history of HIT in 1992, presented in December 1996 with unstable angina and received 0?1 mg/kg/h r-hirudin intravenously for a period of 7 days. Treatment was well tolerated, and the activated partial thromboplastin time (aPTT) was prolonged by 1?5±2 times the normal range. r-Hirudin was switched to oral anticoagulation.
In June 1997, the patient was again referred to the hospital for recurrent cardiac ischaemia. Oral anticoagulation was switched to r-hirudin, because cardiac catheterization was planned. By 2 h after the subcutaneous administration of 25 mg of hirudin, the patient developed a generalized¯ush reaction. The allergic reaction disappeared within 2 h. Antibodies against r-hirudin did not develop. Six weeks later, the patient was referred to another hospital for operation on nifedipin-induced gingivitis. Anticoagulation was switched again from phenprocoumon to r-hirudin. Twenty minutes after the subcutaneous injection of 25 mg of r-hirudin, pruritus, erythema and a generalized¯ush reaction appeared. Symptoms disappeared within 1 h with cortisone and histamine blockers. Ecarin clotting time, which speci®cally determines the inhibition of hirudins on the conversion of meizothrombin to thrombin, increased from 54 s before subcutaneous administration to 106 s and 94 s at 2 h and 6 h, respectively, after subcutaneous administration of r-hirudin (normal range < 55 s). Inhibition of thrombin was measured using the chromogenic S2238 method (normal range < 80 ng/ml). The concentration increased to 320 ng/ml 6 h after subcutaneous administration of r-hirudin. The concentration of r-hirudin was measured using an enzymelinked immunosorbent assay (ELISA; all methods: Song et al, 1999; normal range < 80 ng/ml). The concentration of hirudin was 649 ng/ml 2 h and 1424 ng/ml 6 h after subcutaneous administration of hirudin. No antihirudin antibodies were found. The results are shown in Fig 1 . Antihirudin antibodies were measured by ELISA for the immunoglobulin isotypes (Song et al, 1999) . Plasma IgE, IgM and IgA levels against r-hirudin were always negative.
IgG against r-hirudin did not increase after the ®rst reexposure to subcutaneous r-hirudin. After the second subcutaneous administration, IgG antihirudin antibody levels increased from 0?003 to 1?910 OD after 8 days.
Scratch tests and epicutaneous tests for heparin, lowmolecular-weight heparins, heparinoid and r-hirudin were all negative.
Seven months later, the patient was re-admitted to hospital because of unstable angina. The patient was given 50 mg of PEG-hirudin (Knoll BASF Pharma, Ludwigshafen, Germany) subcutaneously once daily for 2 days. No clinical side-effects occurred. The anticoagulant effects are shown in Fig 2 as well as the time course of the IgG-antihirudin antibody. The effects on ecarin clotting time and the chromogenic thrombin inhibition assay S2238 were as expected. The concentration of PEG-hirudin increased up to 3990 ng/ml and decreased within 48 h to within the normal range in the ELISA (Fig 2) . No changes in platelet count were observed, and no thromboembolic complications occurred during a 3-month observation period.
DISCUSSION
Re-exposure to r-hirudin has been studied only in healthy volunteers (Close et al, 1994) . Allergic reactions occurred in three out of 200 volunteers after the second or third course of subcutaneous r-hirudin. One case report described a patient who developed acute urticaria as a result of the ®fth course of subcutaneous r-hirudin (Bircher et al, 1996) . In the present report, an allergic reaction was described in a HIT patient, who was re-exposed to r-hirudin twice. The patient was treated using subcutaneous PEG-hirudin, and there were no clinical side-effects.
The improved pharmacological performance of PEGproteins compared with their unmodi®ed counterparts prompted their development as therapeutic agents (Delgado et al, 1992) . Speci®c protein domains are hidden by the modi®er and increase the plasma half-life of the protein, while reducing allergenicity and immunogenicity. Despite the reduced immunogenicity of PEG-modi®ed proteins, antibody formation rarely occurs, and the antibodies produced seem to be weaker than those produced against the native protein (Wieder et al, 1979) . Therefore, we decided to use PEGhirudin in the patient with an allergic reaction to the parent compound. As reported in the literature, the pegylated compound showed a dissociation of the allergenicity and immunogenicity in this patient.
After the subcutaneous administration of 25 mg of r-hirudin or 50 mg of PEG-hirudin, the ELISA determined substantially higher plasma concentrations than expected. This ®nding can be explained by the binding of the IgG antihirudin antibody of the patient to PEG-hirudin in plasma and interference with the rabbit antihirudin antibody in the assay. This was supported by the rapid decrease in the plasma concentration of PEG-hirudin within 2 days or less, which is substantially shorter than the plasma half-life of PEG-hirudin. Also, the patient's IgG antihirudin antibody decreased after administration of PEGhirudin and then increased after elimination of the compound. A decrease in the IgG antihirudin antibody has also been reported in a patient after the ®fth course of subcutaneous hirudin (Bircher et al, 1996) .
In conclusion, patients with allergic reactions to r-hirudin may receive short-term treatment with PEG-hirudin as a result of a dissociation of the allergic and immunogenic event of pegylated drugs. Short Report q 2000 Blackwell Science Ltd, British Journal of Haematology 108: 528±530   Fig 1. The time courses of the ecarin clotting time (ECT) expressed in seconds and ng/ml, the thrombin inhibition S2238 assay (ng/ml), the r-hirudin ELISA (ng/ml) and the IgG antihirudin antibody (optical density at 295 nm, OD) are depicted after subcutaneous administration of 25 mg of r-hirudin.
Fig 2.
The time courses of the ecarin clotting time (ECT) expressed in seconds and ng/ml, the thrombin inhibition S2238 assay, the hirudin ELISA (both ng/ml) and the IgG antihirudin antibodies (OD) are depicted after two subcutaneous administrations of 50 mg of PEG-hirudin at 0 h and 24 h.
